本期 13F-HR 中的全部持仓，以及相对上季度的变化。
13F 持仓，最新季度
来源SEC EDGAR13F-HR
Omega Fund Management, LLC (CIK 1637359) reported $185.7M across 10 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: BCAX ($54.1M, 29.14%), NUVB ($45.9M, 24.72%), KMTS ($26.0M, 14.00%), BBOT ($25.1M, 13.50%), BBNX ($20.6M, 11.11%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | BCAX | Bicara Therapeutics Inc. | $54.1M | 29.14% | 1.8M | Trimmed |
| 2 | NUVB | Nuvation Bio Inc. | $45.9M | 24.72% | 8.1M | Hold |
| 3 | KMTS | Kestra Med Technologies Ltd | $26.0M | 14.00% | 1.0M | Hold |
| 4 | BBOT | BridgeBio Oncology Therapeutics Inc. | $25.1M | 13.50% | 3.3M | Hold |
| 5 | BBNX | Beta Bionics Inc. | $20.6M | 11.11% | 1.3M | Hold |
| 6 | ALMS | Alumis Inc. | $6.8M | 3.66% | 241,255 | Hold |
| 7 | SANA | Sana Biotechnology, Inc. | $2.9M | 1.59% | 843,750 | Hold |
| 8 | IMA | ImageneBio, Inc. | $2.7M | 1.45% | 455,361 | Hold |
| 9 | ENGN | enGene Holdings Inc. | $1.5M | 0.82% | 876,357 | Hold |
| 10 | ODTX | Odyssey Therapeutics Inc. | $54,128 | 0.03% | 2,893 | New |
| 11 | REPL | Replimune Group | $0 | 0.00% | 0 | Exited |
来源：SEC 13F 申报文件 · 截至 2026-06-30